{"title":"Corrigendum: Osteopontin Promotes Macrophage M1 Polarization by Activation of the JAK1/STAT1/HMGB1 Signaling Pathway in Nonalcoholic Fatty Liver Disease.","authors":"","doi":"10.14218/JCTH.2021.00474C","DOIUrl":"https://doi.org/10.14218/JCTH.2021.00474C","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.14218/JCTH.2021.00474.].</p>","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"12 1","pages":"119-121"},"PeriodicalIF":3.6,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139512483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Unique Genetic Features of Lean NAFLD: A Review of Mechanisms and Clinical Implications.","authors":"Jasmine Tidwell, George Y Wu","doi":"10.14218/JCTH.2023.00252","DOIUrl":"10.14218/JCTH.2023.00252","url":null,"abstract":"<p><p>Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population. About 20% have a normal body mass index (BMI) and a variant known as lean NAFLD. Unlike typical NAFLD cases associated with obesity and diabetes, lean NAFLD causes liver disease by mechanisms not related to excess weight or insulin resistance. Genetic disorders are among the major factors in developing lean NAFLD, and genome-wide association studies have identified several genes associated with the condition. This review aims to increase awareness by describing the genetic markers linked to NAFLD and the defects involved in developing lean NAFLD.</p>","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"12 1","pages":"70-78"},"PeriodicalIF":3.6,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139512486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qi-Feng Chen, Song Chen, Minshan Chen, N. Lyu, Ming Zhao
{"title":"Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate","authors":"Qi-Feng Chen, Song Chen, Minshan Chen, N. Lyu, Ming Zhao","doi":"10.14218/jcth.2023.00403","DOIUrl":"https://doi.org/10.14218/jcth.2023.00403","url":null,"abstract":"","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"7 6","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139439477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kunli Yin, Kai-Jian Chu, Ming Li, Yu-Xin Duan, Yanxi Yu, Meiqing Kang, Da Fu, Rui Liao
{"title":"Immune Regulatory Networks and Therapy of γδ T Cells in Liver Cancer: Recent Trends and Advancements","authors":"Kunli Yin, Kai-Jian Chu, Ming Li, Yu-Xin Duan, Yanxi Yu, Meiqing Kang, Da Fu, Rui Liao","doi":"10.14218/jcth.2023.00355","DOIUrl":"https://doi.org/10.14218/jcth.2023.00355","url":null,"abstract":"","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"5 3","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139446758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yazan Abboud, Mohamed Ismail, Hamza Khan, Esli Medina-Morales, S. Alsakarneh, F. Jaber, Nikolaos T. Pyrsopoulos
{"title":"Hepatocellular Carcinoma Incidence and Mortality in the USA by Sex, Age, and Race: A Nationwide Analysis of Two Decades","authors":"Yazan Abboud, Mohamed Ismail, Hamza Khan, Esli Medina-Morales, S. Alsakarneh, F. Jaber, Nikolaos T. Pyrsopoulos","doi":"10.14218/jcth.2023.00356","DOIUrl":"https://doi.org/10.14218/jcth.2023.00356","url":null,"abstract":"","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"121 22","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139390679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Editorial Office Of Journal Of Clinical And Translational Hepatology
{"title":"2023 Reviewer Acknowledgement.","authors":"Editorial Office Of Journal Of Clinical And Translational Hepatology","doi":"10.14218/JCTH.2023.000RA","DOIUrl":"https://doi.org/10.14218/JCTH.2023.000RA","url":null,"abstract":"","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"11 7","pages":"1580-1583"},"PeriodicalIF":3.6,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139074254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Antiviral Therapy Favors a Lower Risk of Liver Cirrhosis in HBeAg-negative Chronic Hepatitis B with Normal Alanine Transaminase and HBV DNA Positivity.","authors":"Jing Zhou, Fa-Da Wang, Lan-Qing Li, Yu-Jin Li, Shi-Yan Wang, En-Qiang Chen","doi":"10.14218/JCTH.2023.00272","DOIUrl":"10.14218/JCTH.2023.00272","url":null,"abstract":"<p><strong>Background and aims: </strong>Direct evidence on the outcomes of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients with normal alanine transaminase after long-term antiviral treatment is lacking.</p><p><strong>Methods: </strong>HBeAg-negative patients with normal ALT and positive HBV DNA (≥20 IU/mL) were retrospectively enrolled. The endpoints included virological response (HBV DNA<100 IU/mL), changes in aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 index (FIB-4), and the incidence of liver nodules, cirrhosis, and hepatocellular carcinoma (HCC).</p><p><strong>Results: </strong>This cohort (<i>n</i>=194) was divided into three subgroups, untreated (<i>n</i>=67), treatment-continued (<i>n</i>=87), and treatment-discontinued patients (<i>n</i>=40), with a median follow-up of 54 months. The treatment-continued group achieved 100% (95% CI: 94.7-100) virological response, and significantly reduced APRI and FIB-4 scores (both <i>p</i><0.001). The risk of liver nodules and cirrhosis in that group was reduced by 76% (HR: 0.24, 95% CI: 0.11-0.54, <i>p</i><0.001) and 89% (HR: 0.11, 95% CI: 0.14-0.91, <i>p</i>=0.041) vs. the untreated group and by 77% (HR: 0.23, 95% CI: 0.10-0.49, <i>p</i><0.001) and 95% (HR: 0.05, 95% CI: 0.01-0.44, <i>p</i>=0.006) vs. the treatment-discontinued group. For patients with HBV DNA≥2,000 IU/mL, adherence to treatment lowered the risks of liver cirrhosis by 92% (95% CI: 0.01-0.67) and 93% (95% CI: 0.01-0.53) vs. the untreated and treatment-discontinued patients, respectively. No patient adhering to treatment developed HCC, but one in each of the remaining groups did.</p><p><strong>Conclusions: </strong>Continuous nucleos(t)ide analog (NA) treatment has a satisfactory effectiveness and helps to lower the risk of liver cirrhosis in HBeAg-negative CHB patients with normal alanine transaminase, especially in those with HBV DNA≥2,000 IU/mL.</p>","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"1 1","pages":"1465-1475"},"PeriodicalIF":3.6,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66777826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version).","authors":"Han Wang, Jun Chen, Xin Zhang, Xia Sheng, Xiao-Yan Chang, Jie Chen, Min-Shan Chen, Hui Dong, Guang-Jie Duan, He-Ping Hu, Zhi-Yong Huang, Wei-Dong Jia, Xiao-Qing Jiang, Dong Kuang, Shan-Shan Li, Zeng-Shan Li, Chang-Li Lu, Shu-Kui Qin, Xue-Shan Qiu, Li-Juan Qu, Chun-Kui Shao, Feng Shen, Guo-Ming Shi, Su-Sheng Shi, Yu-Jun Shi, Hui-Chuan Sun, Xiao-Dong Teng, Bin Wang, Zhan-Bo Wang, Tian-Fu Wen, Jia-Mei Yang, Qiao-Qiao Yang, Sheng-Long Ye, Hong-Fang Yin, Zhen-Gang Yuan, Jing-Ping Yun, Feng-Lin Zang, Hong-Qi Zhang, Li-Hong Zhang, Jing-Min Zhao, Jian Zhou, Wei-Xun Zhou, Jia Fan, Xiao-Ping Chen, Wan Yee Lau, Yuan Ji, Wen-Ming Cong","doi":"10.14218/JCTH.2023.00118","DOIUrl":"10.14218/JCTH.2023.00118","url":null,"abstract":"<p><p>Intrahepatic cholangiocarcinoma (iCCA) can originate from the large bile duct group (segment bile ducts and area bile ducts), small bile duct group (septal bile ducts and interlobular bile ducts), and terminal bile duct group (bile ductules and canals of Hering) of the intrahepatic biliary tree, which can be histopathological corresponding to large duct type iCCA, small duct type iCCA and iCCA with ductal plate malformation pattern, and cholangiolocarcinoma, respectively. The challenge in pathological diagnosis of above subtypes of iCCA falls in the distinction of cellular morphologies, tissue structures, growth patterns, invasive behaviors, immunophenotypes, molecular mutations, and surgical prognoses. For these reasons, this expert consensus provides nine recommendations as a reference for standardizing and refining the diagnosis of pathological subtypes of iCCA, mainly based on the 5<sup>th</sup> edition of the World Health Organization Classification of Tumours of the Digestive System.</p>","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"11 7","pages":"1553-1564"},"PeriodicalIF":3.6,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139074256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vy H Nguyen, Audrey Ha, Nicholas Ajit Rouillard, Richard Hieu Le, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H Nguyen
{"title":"Differential Mortality Outcomes in Real-world Patients with Lean, Nonobese, and Obese Nonalcoholic Fatty Liver Disease.","authors":"Vy H Nguyen, Audrey Ha, Nicholas Ajit Rouillard, Richard Hieu Le, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H Nguyen","doi":"10.14218/JCTH.2023.00016","DOIUrl":"10.14218/JCTH.2023.00016","url":null,"abstract":"<p><strong>Background and aims: </strong>Nonalcoholic fatty liver disease (NAFLD) is commonly associated with obesity but can develop in normal-weight people (lean NAFLD). We compared outcomes in lean, overweight, and obese NAFLD.</p><p><strong>Methods: </strong>This retrospective chart review included patients at Stanford University Medical Center with NAFLD confirmed by imaging between March 1995 and December 2021. Lean, overweight, and obese patients had body mass index of <25.0, >25.0 and <29.9, and ≥30.0 kg/m<sup>2</sup> for non-Asian and >23.0 and ≥27.5 for overweight and obese Asian patients.</p><p><strong>Results: </strong>A total of 9061 lean (10.2%), overweight (31.7%), and obese (58.1%) patients were included. Lean patients were 5 years older than obese patients (53±17.4 vs. 48.7±15.1 years), more were female (59.6% vs. 55.2%), white (49.1% vs. 46.5%), had NASH (29.2% vs. 22.5%), cirrhosis (25.3% vs.19.2%), or nonliver cancer (25.3% vs. 18.3%). Fewer had diabetes (21.7% vs. 35.8%) or metabolic comorbidities (all <i>p</i><0.0001). Lean NAFLD patients had liver-related mortality similar to other groups but higher overall (<i>p</i>=0.01) and nonliver-related (<i>p</i>=0.02) mortality. After multivariable model adjustment for covariates, differences between lean and obese NAFLD in liver-related, nonliver-related, and overall mortality (adjusted hazard ratios of 1.34, 1.00, and 1.32; <i>p</i>=0.66, 0.99, and 0.20, respectively) were not significant.</p><p><strong>Conclusions: </strong>Lean NAFLD had fewer metabolic comorbidities but similar adverse or worse outcomes, suggesting that it is not benign. Healthcare providers should provide the same level of care and intervention as for overweight and obese NAFLD.</p>","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"11 7","pages":"1448-1454"},"PeriodicalIF":3.6,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139074255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Focal Nodular Hyperplasia: A Comprehensive Review with a Particular Focus on Pathogenesis and Complications","authors":"Jaimy Villavicencio Kim, George Y. Wu","doi":"10.14218/jcth.2023.00265","DOIUrl":"https://doi.org/10.14218/jcth.2023.00265","url":null,"abstract":"","PeriodicalId":15484,"journal":{"name":"Journal of Clinical and Translational Hepatology","volume":"26 23","pages":""},"PeriodicalIF":3.6,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138950421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}